These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33693560)

  • 1. Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment.
    Van Nieuwenhove E; De Langhe E; Dooley J; Van Den Oord J; Shahrooei M; Parvaneh N; Ziaee V; Savic S; Kacar M; Bossuyt X; Humblet-Baron S; Liston A; Wouters C
    Rheumatology (Oxford); 2021 Nov; 60(11):5436-5446. PubMed ID: 33693560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever.
    Moghaddas F; Llamas R; De Nardo D; Martinez-Banaclocha H; Martinez-Garcia JJ; Mesa-Del-Castillo P; Baker PJ; Gargallo V; Mensa-Vilaro A; Canna S; Wicks IP; Pelegrin P; Arostegui JI; Masters SL
    Ann Rheum Dis; 2017 Dec; 76(12):2085-2094. PubMed ID: 28835462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygous MEFV Gene Variant and Pyrin-Associated Autoinflammation With Neutrophilic Dermatosis: A Family With a Novel Autosomal Recessive Mode of Inheritance.
    Vahidnezhad H; Youssefian L; Saeidian AH; Ziaee V; Mahmoudi H; Parvaneh N; Ashjaei B; Shahrokh S; Kamyab Hesari K; Soltani Zangbar M; Yousefi M; Zeinali S; Uitto J
    JAMA Dermatol; 2021 Dec; 157(12):1466-1471. PubMed ID: 34643647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases.
    Malengier-Devlies B; Metzemaekers M; Gouwy M; Van Nieuwenhove E; Betrains A; Cockx M; Vanbrabant L; Pörtner N; Vercauteren J; De Somer L; Struyf S; Vanderschueren S; De Langhe E; Proost P; Matthys P; Wouters C
    J Clin Immunol; 2021 Jul; 41(5):1072-1084. PubMed ID: 33666778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of interleukin-1 receptor antagonist responsive to anakinra.
    Schnellbacher C; Ciocca G; Menendez R; Aksentijevich I; Goldbach-Mansky R; Duarte AM; Rivas-Chacon R
    Pediatr Dermatol; 2013; 30(6):758-60. PubMed ID: 22471702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Assessment of Disease-Associated Pyrin Variants.
    Chirita D; Jamilloux Y; Henry T; Magnotti F
    Methods Mol Biol; 2022; 2523():179-195. PubMed ID: 35759198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Flow Cytometry-Based Assay for the Functional Classification of MEFV Variants.
    Honda Y; Maeda Y; Izawa K; Shiba T; Tanaka T; Nakaseko H; Nishimura K; Mukoyama H; Isa-Nishitani M; Miyamoto T; Nihira H; Shibata H; Hiejima E; Ohara O; Takita J; Yasumi T; Nishikomori R
    J Clin Immunol; 2021 Aug; 41(6):1187-1197. PubMed ID: 33733382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience.
    Ugurlu S; Ergezen B; Egeli BH; Selvi O; Ozdogan H
    Rheumatology (Oxford); 2021 May; 60(5):2327-2332. PubMed ID: 33295622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.
    Masters SL; Lagou V; Jéru I; Baker PJ; Van Eyck L; Parry DA; Lawless D; De Nardo D; Garcia-Perez JE; Dagley LF; Holley CL; Dooley J; Moghaddas F; Pasciuto E; Jeandel PY; Sciot R; Lyras D; Webb AI; Nicholson SE; De Somer L; van Nieuwenhove E; Ruuth-Praz J; Copin B; Cochet E; Medlej-Hashim M; Megarbane A; Schroder K; Savic S; Goris A; Amselem S; Wouters C; Liston A
    Sci Transl Med; 2016 Mar; 8(332):332ra45. PubMed ID: 27030597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from characterization and treatment of the autoinflammatory syndromes.
    Aksentijevich I; McDermott MF
    Curr Opin Rheumatol; 2017 Mar; 29(2):187-194. PubMed ID: 27906774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
    Calligaris L; Marchetti F; Tommasini A; Ventura A
    Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra.
    Kim BJ; Kim YH; Lee S; Han JH; Lee SY; Seong J; Lee DH; Kim B; Park HR; Carandang M; Oh D; Oh SH; Kim JG; Lee S; Choi BY
    Rheumatology (Oxford); 2021 Mar; 60(3):1523-1532. PubMed ID: 33020839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome.
    van der Meer JW; Simon A
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii23-ii29. PubMed ID: 27856657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism.
    Magnotti F; Chirita D; Dalmon S; Martin A; Bronnec P; Sousa J; Helynck O; Lee W; Kastner DL; Chae JJ; McDermott MF; Belot A; Popoff M; Sève P; Georgin-Lavialle S; Munier-Lehmann H; Tran TA; De Langhe E; Wouters C; Jamilloux Y; Henry T
    Cell Rep; 2022 Oct; 41(2):111472. PubMed ID: 36223753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-demand treatment with anakinra: a treatment option for selected TRAPS patients.
    Grimwood C; Despert V; Jeru I; Hentgen V
    Rheumatology (Oxford); 2015 Sep; 54(9):1749-51. PubMed ID: 26078218
    [No Abstract]   [Full Text] [Related]  

  • 16. Function and mechanism of the pyrin inflammasome.
    Heilig R; Broz P
    Eur J Immunol; 2018 Feb; 48(2):230-238. PubMed ID: 29148036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra.
    Cattalini M; Meini A; Monari P; Gualdi G; Arisi M; Pelucchi F; Bolognini S; Gattorno M; Calzavara-Pinton PG; Plebani A
    Dermatol Online J; 2013 Nov; 19(11):20405. PubMed ID: 24314780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
    Gentileschi S; Rigante D; Vitale A; Sota J; Frediani B; Galeazzi M; Cantarini L
    Clin Rheumatol; 2017 Jul; 36(7):1687-1690. PubMed ID: 28536823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.
    Harrison SR; McGonagle D; Nizam S; Jarrett S; van der Hilst J; McDermott MF; Savic S
    JCI Insight; 2016 May; 1(6):e86336. PubMed ID: 27699261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.